Adverse events associated with first-line treatment
| Regimen . | n . | Any . | Infection . | Neutropenia . | Diabetes . | Psychiatric disorder . |
|---|---|---|---|---|---|---|
| Steroids alone | 142 | 36 (25) | 23 (16) | 2 (1) | 11 (8) | 6 (4) |
| Steroids + cyclophosphamide | 83 | 34* (41) | 22 (27) | 12 (14) | 5 (6) | 3 (4) |
| Rituximab-based regimens | 51 | 19 (37) | 6 (12) | 9 (18) | 11 (22) | 1 (2) |
| Regimen . | n . | Any . | Infection . | Neutropenia . | Diabetes . | Psychiatric disorder . |
|---|---|---|---|---|---|---|
| Steroids alone | 142 | 36 (25) | 23 (16) | 2 (1) | 11 (8) | 6 (4) |
| Steroids + cyclophosphamide | 83 | 34* (41) | 22 (27) | 12 (14) | 5 (6) | 3 (4) |
| Rituximab-based regimens | 51 | 19 (37) | 6 (12) | 9 (18) | 11 (22) | 1 (2) |
Adverse events are reported in association with first-line immunosuppressive treatments. Some persons had more than 1 adverse event, so numbers do not tally across the table.
Four patients received intravenous cyclophosphamide and 30 patients received oral cyclophosphamide.